Logo image
Defining a New Classification System for the Surgical Management of Neuroendocrine Tumor Liver Metastases
Journal article   Open access   Peer reviewed

Defining a New Classification System for the Surgical Management of Neuroendocrine Tumor Liver Metastases

Kelly M. Mahuron and Gagandeep Singh
Journal of Clinical Medicine, Vol.12(7)
2023

Abstract

antineoplastic agent cancer chemotherapy cancer radiotherapy cancer surgery cytoreductive surgery human liver metastasis liver parenchyma liver transplantation longevity neuroendocrine tumor outcome assessment peptide receptor radionuclide therapy primary tumor Review systemic therapy
Although rarely curative, hepatic cytoreduction of neuroendocrine tumor liver metastases (NETLM) is associated with improved symptom control and prolonged survival. Preoperative 68Ga DOTATATE and gadoxetic acid-enhanced liver MRI can improve characterization of hepatic disease extent to improve surgical clearance, and resection of the primary tumor is associated with improved survival regardless of whether the liver metastases are treated. As parenchymal-sparing surgical techniques and the lowering of the debulking threshold have expanded the numbers of eligible NETLM patients for hepatic cytoreduction, we propose a new classification system to help guide surgical management. A multimodal approach that includes surgery, liver-directed therapies, and systemic therapies has improved outcomes and increased longevity for patients with well-differentiated metastatic NET. © 2023 by the authors.
url
https://doi.org/10.3390/jcm12072456View
Published (Version of record) Open

Metrics

3 Record Views

Details

Logo image